M. Corona Gainford

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli et al. · The Lancet Oncology · 2020 · 251 citations

Breast Oncology, Standard-of-care Chemotherapy, Medicine +7

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

Martin R. Stockler, Vernon Harvey, Prudence A. Francis et al. · Journal of Clinical Oncology · 2011 · 150 citations · Full text

Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

Matthew P. Goetz, Miguel Martín, Eriko Tokunaga et al. · The Oncologist · 2020 · 52 citations · Full text

A practical guide to the management of menopausal symptoms in breast cancer patients

M. Corona Gainford, Christine Simmons, Huong D. Nguyen et al. · Supportive Care in Cancer · 2005 · 21 citations

Nursing, Breast Oncology, Breast Cancer Patients +12

Malignant Transformation Within Ovarian Dermoid Cysts: An Audit of Treatment Received and Patient Outcomes. An Australia New Zealand Gynaecological Oncology Group (ANZGOG) and Gynaecologic Cancer Intergroup (GCIG) Study

M. Corona Gainford, Anna V. Tinker, Jonathan Carter et al. · International Journal of Gynecological Cancer · 2010 · 19 citations